CompletedPhase 4

IMProving Executive Function Study

United States69 participantsStarted 2017-09-22

Plain-language summary

This is a double-blind, placebo-controlled, crossover study testing whether Vyvanse (lisdexamfetamine; LDX) improves executive functioning (EF) in 100 postmenopausal women who report onset of EF difficulties after oophorectomy. This study involves magnetic resonance imaging (MRI) to see how LDX affects brain chemistry while undergoing two 6-week trials of the study drug and placebo capsules. UPDATE: We have recently updated this protocol (09/2020) to offer a remote version of the study that can be completed entirely from the participant's home. This alternate version of the study eliminates travel, the MRI, and blood draws.

Who can participate

Age range35 Years – 58 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female; * Age 35-58; * Have undergone risk-reducing bilateral salpingo-oophorectomy (RRSO) within the previous 15 years AND were premenopausal at the time of RRSO; * Score of ≥ 20 on the Brown Attention Deficit Disorder Scale (BADDS); * Onset of executive function difficulties occurred post RRSO; * Clean urine drug screen (nicotine and marijuana are permissible); * Are fluent in written and spoken English; * Are able to give written informed consent (obtained at screening visit); * Have a high school diploma or equivalent degree (i.e., GED), as per subject report; * If using aromatase inhibitors or tamoxifen: Must have been on a stable dose for at least 6 months; * If completing visits remotely: Must have access to a telecommunications application (i.e., Skype), email, scanner/fax machine, and a private area that enables the protection of participant confidentiality. Exclusion criteria: * Current, untreated psychiatric disorder; * Substance use disorder within the previous 3 years; * Lifetime history of ADHD or psychotic disorder including bipolar disorder, schizoaffective disorder, and schizophrenia; * Lifetime history of stimulant abuse or dependence; * Regular use of psychotropic medications except selective serotonin reuptake inhibitors (SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), bupropion, zolpidem, gabapentin, or buspirone; * Chemotherapy within the past year; * Previous history of sensitivity or adverse reaction to lisdexamfetam…

What they're measuring

Brown Attention Deficit Disorder Scale (BADDS) Change Score (End of Trial Minus Baseline).

Timeframe: Outcome measure change score represents end of trial (6 weeks) minus baseline.

Trial details

NCT IDNCT03187353

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-30

Results submitted2023-05-02